NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Health Technology Appraisal

Non-bisphosphonates for treating osteoporosis [ID901]

Provisional matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Actavis UK (raloxifene) • Amgen (denosumab, romosozumab) • Consilient Health (raloxifene) • Daiichi Sankyo (raloxifene) • Eli Lilly (teriparatide) • Mylan UK (raloxifene) • Radius Health (abaloparatide) • Sandoz (raloxifene) • UCB (romosozumab) Patient/carer groups • Action on Pain • Arthritis and Musculoskeletal Alliance (ARMA) • BackCare • Disability Rights UK • Leonard Cheshire Disability • Muslim Council of Britain • National Osteoporosis Society • Pain Concern • Pain Relief Foundation • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • Women's Health Concern Professional groups • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Menopause Society • British Orthopaedic Association • British Society for Rheumatology • British Society of Rehabilitation Medicine • Physiotherapy Pain Association	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Potential comparator manufacturers • Accord Healthcare (alendronate, ibandronate, zoledronate) • Actavis UK (alendronate, ibandronate, risedronate, zoledronate) • Amneal Pharma Europe (zoledronate) • Aurobindo (alendronate, risedronate) • Consilient Health (ibandronate) • Creo Pharma (alendronate) • Dr Reddy's Laboratories (zoledronate) • Hospira UK (zoledronate) • Internis (alendronate) • Intrapharm Laboratories (zoledronate) • Medac (zoledronate) • Merck Sharp & Dohme (alendronate) • Mylan UK (alendronate, ibandronate, zoledronate)

Consultees	**Commentators (no right to submit or appeal)**
• Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • NHS Barnet CCG • NHS England • NHS Milton Keynes CCG • Welsh Government	• Novartis Pharmaceuticals (zoledronate) • Ranbaxy (ibandronate, zoledronate) • Rosemont (alendronate) • Sandoz (risedronate) • Seacross Pharmaceuticals (zoledronate) • Warner Chilcott UK (risedronate) • Zentiva (alendronate, ibandronate) <u>Relevant research groups</u> • Bone Research Society • Chronic Pain Policy Coalition (CPPC) • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Musculoskeletal Group • Institute for Ageing and Health • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK <u>Associated Guideline Groups</u> • National Clinical Guideline Centre • National Collaborating Centre for Women and Children's Health • National Osteoporosis Guideline Group <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.